Merck's lovastatin
Executive Summary
Firm's cholesterol-lowering agent will be reviewed at the next meeting of FDA's Endocrinologic and Metabolic Drugs Advisory Committee, tentatively scheduled for Feb. 19. Merck filed an NDA for lovastatin in November.